Trial Information

Summary: HER2-positive Breast Cancer Study CRAD001J2101

Novartis Oncology is conducting this clinical trial is to determine whether adding the study drug RAD001 to two other anti-cancer agents, trastuzumab and paclitaxel, is safe and has beneficial effect in participants with HER2-positive metastatic breast cancer. The study drug RAD001 is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).The study drug will be administered on a daily basis or a weekly basis depending on the treatment group assigned to the participant. Trastuzumab will be given as infusions directly into a vein in 28-day cycles on Day 1, 8, 15 and 22 of each cycle. Paclitaxel will also be given as infusions directly into a vein in 28-day cycles on Day 1, 8, 15 of each cycle. Patients will receive at least 6 cycles of treatment.

For more information about this clinical trial, visit www.NovartisClinicalTrials.com

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: November 21, 2008 at 2:56:20 PM